European Commission Grants RZ-001 Orphan Drug Designation for Glioma
Rznomics said the European Commission granted orphan medicinal product designation to its RNA-based gene therapy candidate RZ-001 for glioma.
Story updates
05:32:41 AM UTC
SquawkNews
Rznomics Inc. said the European Commission granted Orphan Medicinal Product Designation to RZ-001 (taspitimagene advec) for glioma, following a positive EMA COMP opinion. The therapy already holds FDA ODD, Fast Track for HCC and GBM, and RMAT for HCC.Material DetailsContext by AI AnalystThis is an…